Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis

• Published in: Irish journal of medical science 2023-12, Vol.192 (6), p.2801-2808
• Main Authors: Fatima, Kaneez, Jamil, Zainab, Faheem, Samar, Adnan, Alishba, Javaid, Syed Sarmad, Naeem, Hafsa, Mohiuddin, Neha, Sajid, Anosha, Ochani, Sidhant
• Format: Article
• Language: English
• Subjects: Family Medicine; General Practice; Internal Medicine; Medicine; Medicine & Public Health; Review Article
• ISSN: 0021-1265; 1863-4362
• DOI: 10.1007/s11845-023-03388-5

Objective Polycystic Ovary Syndrome is the most prevalent hormonal disorder in females. Over the years, metformin (MET) has become the first-line choice of treatment; however, due to its gastrointestinal side effects, a more recent drug, myo-inositol (MI), has been introduced. We aim to conduct a systematic review and meta-analysis to compare the effects of MET and MI on hormonal and metabolic parameters. Materials and methods Authors extensively searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science for randomized clinical trials (RCTs) until August 2021. Eight ( n  = 8) articles were included, with a total sample size of 1088, of which 460 patients received MET, 436 received MI, and 192 received a combination of both. Standard mean differences (SMDs) and Confidence Intervals (CIs) were used for data synthesis, and forest plots were made using Review Manager 5.4 for Statistical Analysis using the random-effect model. Results The meta-analysis indicates that there is no significant difference between MET and MI in terms of their effects on BMI (SMD = 0.16, 95% CI: − 0.11 to 0.43, p  = 0.24), fasting insulin (SMD = 0.00, 95% CI: − 0.26 to 0.27, p  = 0.97), fasting blood sugar (SMD = 0.11, 95% CI: − 0.31to 0.53, p  = 0.60), HOMA index (SMD = 0.09, 95% CI: − 0.20 to 0.39, p  = 0.50), and LH/FSH (SMD = 0.20, 95% CI: − 0.24 to 0.64, p  = 0.37). BMI, fasting blood sugar, and LH/FSH ratio reported moderate heterogeneity because of the varying number of study participants. Conclusion Our meta-analysis comparing hormonal and metabolic parameters between MET and MI did not show much significant difference, indicating both drugs are equally beneficial in improving metabolic and hormonal parameters in patients with PCOS.